{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.8","upperLimit":"12","value":"12"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Median time (number of days) to neutrophil engraftment was determined as first of three consecutive days with absolute neutrophil count (ANC) \\> 500/ul or first day with ANC \\> 1000/ul in the absence of growth factor support.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Patients received 100mg desipramine hydrochloride PO daily from Day -3 to Day +4 (8 days total) and filgrastim PO BID from Day +1 to Day +4. Complete blood count (CBC) and peripheral blood CD34+ counts were determined on Day +4 and Day +5. Leukapheresis was started when peripheral blood CD34+ count exceeded 10/uL. If CD34+ counts were \\<10/uL on Day +5, plerixafor was added as a salvage therapy. Daily leukapheresis was performed with four times the estimated blood volume during each collection until a target cell dose of at least 5x10\\^6 cells/kg was reached. If the collected CD34+ cell dose was \\<0.5x10\\^6 on two consecutive days, aperheris was stopped and the patient was taken off study.\n\nDespiramine hydrochloride: PO Filgrastim: PO","id":"OG000","title":"Treatment (Desipramine, Filgrastim)"}],"paramType":"MEDIAN","populationDescription":"6 participants underwent stem cell transplantation and completed the full study protocol.","reportingStatus":"POSTED","timeFrame":"Up to 1 week following completion of study treatment, up to 15 days","title":"Median Time to Neutrophil Engraftment","type":"SECONDARY","unitOfMeasure":"number of days"}